Anbio Biotechnology · Healthcare · Medical Instruments & Supplies
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$26.05
−$1.51 (−5.46%) 4:00 PM ET
After hours$27.55
+$1.51 (+5.78%) 4:56 PM ET
Prev closePrevC$27.55
OpenOpen$27.74
Day highHigh$30.04
Day lowLow$25.60
VolumeVol160,604
Avg volAvgVol75,382
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.13B
Sector
Healthcare
AI report sections
MIXED
NNNN
Anbio Biotechnology
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+148% (Above avg)
Vol/Avg: 2.48×
RSI
52.60(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.04 (Strong)
MACD: -0.14 Signal: -0.18
Short-Term
+0.49 (Strong)
MACD: -0.75 Signal: -1.24
Long-Term
+0.21 (Strong)
MACD: -1.60 Signal: -1.80
Intraday trend score
52.00
LOW47.00HIGH65.50
Latest news
NNNN•3 articles•Positive: 3Neutral: 0Negative: 0
PositiveBenzinga• Piero Cingari
Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400%
The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.
EPSMMENSANPADGNXIPOstock marketTrumpinvestment
Sentiment note
Substantial 470.34% stock price growth since February IPO
PositiveGlobeNewswire Inc.• Michael Lau
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Anbio Biotechnology launched a Chikungunya IgM/IgG Rapid Test and an AP-100 Ultra-Fast PCR system to support rapid diagnostic testing for infectious diseases, enabling quick detection of pathogens in both centralized and decentralized healthcare settings.
Company is proactively developing innovative diagnostic technologies to address emerging global health challenges, demonstrating technological advancement and commitment to rapid outbreak response
PositiveGlobeNewswire Inc.• N/A
Amaran Biotech Signs MOU with Nippon Fine Chemical
Amaran Biotechnology, a subsidiary of OBI Pharma, and Nippon Fine Chemical, a Japanese company, have signed an MOU to collaborate in nanoparticle-based drug CDMO manufacturing. The partnership aims to leverage their respective strengths to expand their presence in Taiwan, Japan, and international CDMO markets.
NNNNAmaran BiotechnologyNippon Fine ChemicalZillion Fine Chemicalsnanoparticle-based drugCDMOcollaboration
Sentiment note
The article highlights Amaran Biotechnology's state-of-the-art manufacturing facility, industry-leading aseptic filling line, and extensive experience in pharmaceutical production, which have earned the trust of Nippon Fine Chemical. The collaboration is expected to create synergistic business opportunities and expand their presence in the CDMO market.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
